Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers

Figure 2

Micro-CT 3D images representing whole sample: ‘‘simvastatin-containing PCL scaffolds’’; PCL scaffold without simvastatin; ‘‘simvastatin-embedded PCL scaffolds’’; and critical size defect without any scaffold (control group). (a) 3 months and (b) 6 months; reproduced with permission from [36].

(a)

(b)